Bloom N D, Norbergs D A, Sherman B, Sadjadi M, Ramaswamy G, Jacobs R, Ackerman N
Department of Surgery, Metropolitan Hospital Center, New York, NY 10029.
Mol Biother. 1990 Jun;2(2):121-4.
The antitumor activity of recombinant human tumor necrosis factor was studied in vivo as a single agent and in combination with a conventional chemotherapeutic agent. Dosages of tumor necrosis factor of 100 micrograms, 50 micrograms, and 25 micrograms were injected intraportally in Sprague-Dawley rats containing hepatic implants of Walker carcinosarcoma. An effect on the tumor was seen but was associated with a significant acute mortality. Lower dosages of tumor necrosis factor, 10 micrograms, 5 micrograms, and 1 microgram, administered with 10 mg/kg of doxorubicin (Adriamycin) significantly enhanced the antitumor effect of doxorubicin without an acute mortality. This suggests that lower dosages of tumor necrosis factor with conventional chemotherapy may augment the latter's effect without any added toxicity.
研究了重组人肿瘤坏死因子作为单一药物以及与传统化疗药物联合使用时的体内抗肿瘤活性。将100微克、50微克和25微克剂量的肿瘤坏死因子经门静脉注射到植入了Walker癌肉瘤的Sprague-Dawley大鼠体内。观察到对肿瘤有作用，但伴有显著的急性死亡率。10微克、5微克和1微克较低剂量的肿瘤坏死因子与10毫克/千克阿霉素（ Adriamycin）联合使用时，显著增强了阿霉素的抗肿瘤作用，且无急性死亡率。这表明较低剂量的肿瘤坏死因子与传统化疗联合使用可能增强后者的疗效，且无额外毒性。
